PeptiDream Inc.

PeptiDream Inc.

PeptiDream was founded in Japan and maintains dual headquarters in Kawasaki and New Haven, positioning itself as a platform company within the global peptide drug discovery ecosystem. The firm describes its mission as creating next-generation medicines that transform medical practice and patient outcomes. PeptiDream's core strategic asset is the Peptide Discovery Platform System (PDPS), a proprietary drug discovery technology. The platform supports preclinical chemistry, biology, protein structure analysis, bioinformatics, modeling, pharmacological profiling, and translational research. The firm partners with domestic and international pharmaceutical companies and research institutions to expand its network. Geographic focus spans Japan and the United States, with additional outposts likely supporting global collaborations. The firm's team size and total deal count are not publicly disclosed. No recent operational events were available in the public domain. PeptiDream's structural distinction lies in its function as a technology platform rather than a traditional drug developer. It licenses its PDPS system to partners who advance candidates through clinical stages, generating revenue through upfront payments, milestones, and royalties — a model that distributes risk across multiple programs.